FinancialBuzz.com: Advances in Biotechnology Sector

NEW YORK, January 9, 2017 /PRNewswire/ --

http://www.Financialbuzz.com - The biotechnology industry is very diverse. Technological innovation and new therapeutic platforms are consistently being developed by biotechs and extensively used in clinical trials. A new research report by Grand View Research, Inc. estimates that the global biotechnology market size is expected to reach USD 604.40 billion by 2020. The report indicates that increasing demand for biotechnology based diagnostics and therapeutics solutions such as recombinant technology, red biotechnology and DNA sequencing is expected to drive market growth. Cell MedX Corp. (OTC: CMXC), Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS), Impax Laboratories Inc. (NASDAQ: IPXL), MannKind Corporation (NASDAQ: MNKD), Amicus Therapeutics (NASDAQ: FOLD)

With all the advances made in the therapeutic field, some diseases remain a major concern, effecting many, like diabetes, Parkinson's, and others. Diabetes is one of the world's oldest diseases and it has been centuries since this syndrome was first recognized, yet, it is menacing as throughout much of the world, it remains hidden. According to IDF Diabetes Atlas, a there are 382 million people living with diabetes worldwide. By 2035, 592 million people or one person in ten will have the disease. As for Parkinson's disease, there no blood or laboratory test for accurate diagnostic, and therefore it is a difficult disease to detect in its early stages.  

Cell MedX Corp. (OTCQB: CMXC) is a development stage focused on the development and commercialization of therapeutic products for patients with various diseases, including diabetes, Parkinson's disease, high blood pressure, and other health conditions. The Company, through its subsidiary Avyonce Cosmedics Inc., is involved in carrying out observational studies using eBalance Technology. The eBalance Technology is used for the use of micro currents for the treatment of diabetes and related diseases. The Company is currently developing a family of devices based on the eBalance Technology.

Cell Medx Corp. today announced that, "that it has received its first eBalance Pro wellness devices ready for commercial distribution. These wellness devices are designed to promote general wellness and alleviate pain caused by chronic conditions such as: sciatica, neuropathy and arthritic pain.

The eBalance Pro wellness device is an all-in-one, portable and fully automated microcurrent delivery system. This cutting-edge device's software uses biofeedback algorithms to identify specific and personalized microcurrent frequencies to alleviate what are, in many cases, painful conditions. This device is based on the Company's original eBalance Pro which continues to receive positive feedback. These observations are currently being conducted in Asia, Europe and North America.

Mr. McEnulty, the Company's CEO, stated: "We are very excited to receive the new model eBalance Pro wellness devices. Our excitement is based on our belief that our eBalance technology has effected positive change in the overall wellbeing of those currently engaged in observations."

Biopharmaceutical company, MannKind Corporation (NASDAQ: MNKD) is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, is a man-made, mealtime insulin that is inhaled and used to control high blood sugar in adults with diabetes mellitus through its Technosphere formulation technology. Technosphere is a drug delivery platform that may allow the oral inhalation of a range of therapeutics. Technosphere powders are based on the Company's fumaryl diketopiperazine, which is a potential of Hydrogen-sensitive organic molecule that self-assembles into small particles under acidic conditions. The Company has also created a range of breath-powered, dry powder inhalers. Its inhalers can be produced in both a reusable and a single-use format.

Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) has announced the FDA has approved for the review the New Drug Application for ADS-5102 extended-release capsules, for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. "This is an important milestone for patients, physicians and Adamas, as we are one step closer to approval of ADS-5102 for Parkinson's disease patients with levodopa-induced dyskinesia, which is an existing gap in their treatment journey," said Gregory T. Went, Ph.D., Chairman and Chief Executive Officer of Adamas Pharmaceuticals, Inc. "Over time, 90% of patients on levodopa therapy suffer from levodopa-induced dyskinesia. Currently, there is no FDA approved medicine for levodopa-induced dyskinesia for patients with Parkinson's disease. If approved, ADS-5102 will be the first and only medicine for Parkinson's disease patients with levodopa-induced dyskinesia."

Impax Laboratories Inc. (NASDAQ: IPXL) segments include Impax Generics and Impax Specialty Pharma. The Impax Generics segment is focused on the development, manufacture, sale and distribution of its generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are marketed under their established drug names. The Impax Specialty Pharma segment is engaged in the promotion, sale and distribution of various branded products, including its branded pharmaceutical product, Rytary, an extended-release treatment for Parkinson's disease with a combination of carbidopa and levodopa. Levodopa is transformed by the body and the brain into a substance that helps to decrease tremors and other symptoms of Parkinson disease. Carbidopa helps levodopa to reach the brain.

Amicus Therapeutics (NASDAQ: FOLD) is currently in study of Pompe disease patients that are currently receiving enzyme-replacement therapy. The purpose of the study is to find out if the co-administration of investigational new drugs ATB200 and AT2221 is safe in adults with Pompe disease. Pompe disease is an inherited Lysosomal Storage Disorder caused by a deficiency of the enzyme acid alpha-glucosidase. Progressive accumulation of glycogen is said to lead to the illness and death associated with Pompe disease, with muscle weakness and respiratory insufficiency.

Please SIGN UP NOW at http://www.FinancialBuzz.com To Receive Alerts on Trending Financial News from all these companies. "The Latest Buzz in Financial News"

Subscribe Now! Watch us report from NYSE https://www.youtube.com/FinancialBuzzMedia

Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz

Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz

Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/

About FinancialBuzz.com

FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR branding, marketing and advertising for third parties for disseminating news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com the "Site") is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and PR marketing firm enters into service agreements with the companies which are the subject to the articles posted on the Site for advertising such companies. Financialbuzz.com expects to be compensated six thousand dollars for financial news dissemination and PR services by a third party non affiliate for cell medx corp. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on this site along with other financial news PR media services. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com does not undertake to update any of the information on the Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on the Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use. Please visit: http://www.financialbuzz.com

For further information:

Media Contact: info@financialbuzz.com , +1-877-601-1879

SOURCE FinancialBuzz.com